67 related articles for article (PubMed ID: 26369711)
41. Long-term effects of natural amino acids on infection with Chlamydia trachomatis.
Gussmann J; Al-Younes HM; Braun PR; Brinkmann V; Meyer TF
Microb Pathog; 2008 May; 44(5):438-47. PubMed ID: 18222624
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of growth of Chlamydia trachomatis by the calcium antagonist verapamil.
Shainkin-Kestenbaum R; Winikoff Y; Kol R; Chaimovitz C; Sarov I
J Gen Microbiol; 1989 Jun; 135(6):1619-23. PubMed ID: 2559152
[TBL] [Abstract][Full Text] [Related]
43. Potential of a novel polyherbal formulation BASANT for prevention of Chlamydia trachomatis infection.
Bhengraj AR; Dar SA; Talwar GP; Mittal A
Int J Antimicrob Agents; 2008 Jul; 32(1):84-8. PubMed ID: 18524545
[TBL] [Abstract][Full Text] [Related]
44. 4-Chloroisocoumarins as Chlamydial Protease Inhibitors and Anti-Chlamydial Agents.
Phillips MJA; Huston WM; McDonagh AM; Rawling T
Molecules; 2024 Mar; 29(7):. PubMed ID: 38611800
[TBL] [Abstract][Full Text] [Related]
45. Chlamydia trachomatis utilizes the mammalian CLA1 lipid transporter to acquire host phosphatidylcholine essential for growth.
Cox JV; Abdelrahman YM; Peters J; Naher N; Belland RJ
Cell Microbiol; 2016 Mar; 18(3):305-18. PubMed ID: 26381674
[TBL] [Abstract][Full Text] [Related]
46. Quantification of serine protease HtrA molecules secreted by the foodborne pathogen
Neddermann M; Backert S
Gut Pathog; 2019; 11():14. PubMed ID: 31044013
[TBL] [Abstract][Full Text] [Related]
47. Red Fluorescent
Mojica SA; Eriksson AU; Davis RA; Bahnan W; Elofsson M; Gylfe Å
Front Microbiol; 2018; 9():3151. PubMed ID: 30619216
[TBL] [Abstract][Full Text] [Related]
48. Chlamydial Antibiotic Resistance and Treatment Failure in Veterinary and Human Medicine.
Borel N; Leonard C; Slade J; Schoborg RV
Curr Clin Microbiol Rep; 2016; 3():10-18. PubMed ID: 27218014
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of antimicrobial resistance and treatment failures for Chlamydia trachomatis: a meeting report.
Wang SA; Papp JR; Stamm WE; Peeling RW; Martin DH; Holmes KK
J Infect Dis; 2005 Mar; 191(6):917-23. PubMed ID: 15717267
[TBL] [Abstract][Full Text] [Related]
50. In vitro susceptibility of recent Chlamydia trachomatis clinical isolates to the CtHtrA inhibitor JO146.
Ong VA; Lawrence A; Timms P; Vodstrcil LA; Tabrizi SN; Beagley KW; Allan JA; Hocking JS; Huston WM
Microbes Infect; 2015; 17(11-12):738-44. PubMed ID: 26369711
[TBL] [Abstract][Full Text] [Related]
51. The protease inhibitor JO146 demonstrates a critical role for CtHtrA for Chlamydia trachomatis reversion from penicillin persistence.
Ong VA; Marsh JW; Lawrence A; Allan JA; Timms P; Huston WM
Front Cell Infect Microbiol; 2013; 3():100. PubMed ID: 24392355
[TBL] [Abstract][Full Text] [Related]
52. CtHtrA: the lynchpin of the chlamydial surface and a promising therapeutic target.
Marsh JW; Ong VA; Lott WB; Timms P; Tyndall JD; Huston WM
Future Microbiol; 2017 Jul; 12():817-829. PubMed ID: 28593794
[TBL] [Abstract][Full Text] [Related]
53. Identification of a serine protease inhibitor which causes inclusion vacuole reduction and is lethal to Chlamydia trachomatis.
Gloeckl S; Ong VA; Patel P; Tyndall JD; Timms P; Beagley KW; Allan JA; Armitage CW; Turnbull L; Whitchurch CB; Merdanovic M; Ehrmann M; Powers JC; Oleksyszyn J; Verdoes M; Bogyo M; Huston WM
Mol Microbiol; 2013 Aug; 89(4):676-89. PubMed ID: 23796320
[TBL] [Abstract][Full Text] [Related]
54. Optimization of peptide-based inhibitors targeting the HtrA serine protease in Chlamydia: Design, synthesis and biological evaluation of pyridone-based and N-Capping group-modified analogues.
Hwang J; Strange N; Phillips MJA; Krause AL; Heywood A; Gamble AB; Huston WM; Tyndall JDA
Eur J Med Chem; 2021 Nov; 224():113692. PubMed ID: 34265463
[TBL] [Abstract][Full Text] [Related]
55. Chlamydia Serine Protease Inhibitor, targeting HtrA, as a New Treatment for Koala Chlamydia infection.
Lawrence A; Fraser T; Gillett A; Tyndall JD; Timms P; Polkinghorne A; Huston WM
Sci Rep; 2016 Aug; 6():31466. PubMed ID: 27530689
[TBL] [Abstract][Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
